A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer

Area of Science:

• Oncology
• Pharmacology
• Dermatology

Background:

• Olaparib is FDA-approved for ovarian and metastatic breast cancer with germline BRCA mutations.
• Expanded use necessitates monitoring for novel adverse events.
• PARP inhibitors represent a significant advancement in targeted cancer therapy.

Observation:

• A patient with metastatic breast cancer and a germline BRCA2 mutation developed erythema nodosum.
• The rash appeared shortly after initiating olaparib and recurred upon re-challenge.
• Erythema nodosum is a rare but notable adverse event associated with olaparib therapy.

Findings:

• The patient's erythema nodosum resolved with prednisone therapy and/or temporary olaparib discontinuation.
• Subsequent olaparib re-initiation at adjusted doses (capsules and tablets) resulted in attenuated erythema nodosum episodes.
• The patient was able to continue olaparib therapy without requiring cessation or steroid treatment.

Implications:

• This case highlights erythema nodosum as a potential adverse event of olaparib in BRCA-mutated breast cancer.
• Management strategies involving dose modification and short-term corticosteroids may allow for continued olaparib treatment.
• Further research into the mechanisms and management of olaparib-induced skin reactions is warranted.